Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
6.26
-0.05 (-0.79%)
Aug 25, 2026, 10:03 AM EDT - Market open
Aclaris Therapeutics Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Aclaris Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $10.2. The average 1-year stock price forecast is 62.94% higher than the current stock price, while the lowest is $4.00 (-36.10%) and the highest is $16 (+155.59%).
Price Target: $10.2 (+62.94%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Aclaris Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 8 | 9 | 9 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 10 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $16 | Buy | Reiterates | $16 | +155.59% | Aug 10, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $11 | Buy | Maintains | $11 | +75.72% | Aug 7, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $13 | Buy | Maintains | $13 | +107.67% | Aug 6, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains $10 | Buy | Maintains | $10 | +59.74% | Aug 6, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $12 | Buy | Reiterates | $12 | +91.69% | May 11, 2026 |
Financial Forecast
Revenue This Year
6.29M
from 7.83M
Decreased by -19.67%
Revenue Next Year
5.18M
from 6.29M
Decreased by -17.58%
EPS This Year
-0.65
from -0.53
EPS Next Year
-0.81
from -0.65
EPS and Forward PE are based on non-GAAP adjusted numbers.